Lee Chien-Ying, Wei Cheng-Chung, Yu Min-Chien, Lin Ching-Che, Sheu Shuenn-Jyi, Yang Jen-Hung, Chiang Chien-Ying, Huang Kuang-Hua, Kuan Yu-Hsiang
Department of Pharmacology, Chung Shan Medical University, Taichung 40242, Taiwan, R.O.C.; Department of Pharmacy, Chung Shan Medical University Hospital, Taichung 40242, Taiwan, R.O.C.; Department of Medicine, Chung Shan Medical University, Taichung 40242, Taiwan, R.O.C.
Department of Medicine, Chung Shan Medical University, Taichung 40242, Taiwan, R.O.C.; Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung 40242, Taiwan, R.O.C.
Exp Ther Med. 2017 Jan;13(1):194-202. doi: 10.3892/etm.2016.3935. Epub 2016 Nov 30.
The aim of the present study was to evaluate the treatment effects of BeauTop in alopecia by observing its effectiveness in improving androgenetic alopecia. Hair growth was observed using a dermatoscope and clinical photos, and was scored by three dermatologists. Dermatologists evaluated and selected suitable participants for this study using the Norwood scale or Ludwig scale. A total of 40 participants with androgenetic alopecia were recruited in this study, and 32 participants completed the 6-month trial. The results revealed that in the BeauTop treatment group, 9/17 participants (52.9%) showed increased hair growth. Changes in hair growth were as follows: No change, 47.1% patients; minimally improved, 5.9% patients; moderately improved, 29.4% patients; and significantly improved, 17.6% patients. In the placebo group, 2/15 participants (13%) showed increased hair growth. A Chi-square test was performed and attained a value of 0.01<P<0.025, indicating a significant difference between the treatment and placebo groups. In addition, blood tests indicated that BeauTop has minimal effects on dehydroepiandrosterone, testosterone and estradiol. This suggests that the mechanism of action of BeauTop varies from that of finasteride. Finasteride is an inhibitor of type II 5αR; BeauTop may enhance hair follicle activities via growth factor. The biochemical analyses of participants were normal in the treatment and placebo groups, and no adverse reactions were observed. The average white blood cell count (WBC) for the treatment group compared with the control group was significantly increased (6770/mm vs. 7560/mm, respectively; P<0.014) at week 4, and significantly decreased at week 24 (6240/mm, P<0.493). In conclusion, BeauTop effectively improves male and female androgenetic alopecia.
本研究的目的是通过观察BeauTop对改善雄激素性脱发的有效性，来评估其在脱发治疗中的效果。使用皮肤镜和临床照片观察头发生长情况，并由三位皮肤科医生进行评分。皮肤科医生使用诺伍德量表或路德维希量表评估并挑选适合本研究的参与者。本研究共招募了40名雄激素性脱发患者，32名参与者完成了为期6个月的试验。结果显示，在BeauTop治疗组中，17名参与者中有9名（52.9%）头发生长增加。头发生长变化如下：无变化，47.1%的患者；改善不明显，5.9%的患者；中度改善，29.4%的患者；显著改善，17.6%的患者。在安慰剂组中，15名参与者中有2名（13%）头发生长增加。进行卡方检验，得到的值为0.01<P<0.025，表明治疗组和安慰剂组之间存在显著差异。此外，血液检测表明BeauTop对脱氢表雄酮、睾酮和雌二醇的影响极小。这表明BeauTop的作用机制与非那雄胺不同。非那雄胺是II型5α还原酶的抑制剂；BeauTop可能通过生长因子增强毛囊活性。治疗组和安慰剂组参与者的生化分析均正常，未观察到不良反应。治疗组与对照组相比，第4周时平均白细胞计数（WBC）显著增加（分别为6770/mm和7560/mm；P<0.014），第24周时显著降低（6240/mm，P<0.493）。总之，BeauTop能有效改善男性和女性雄激素性脱发。
